97 related articles for article (PubMed ID: 34570376)
1. Inhibition of tumor-associated macrophages by trabectedin improves the antitumor adaptive immunity in response to anti-PD-1 therapy.
Belgiovine C; Frapolli R; Liguori M; Digifico E; Colombo FS; Meroni M; Allavena P; D'Incalci M
Eur J Immunol; 2021 Nov; 51(11):2677-2686. PubMed ID: 34570376
[TBL] [Abstract][Full Text] [Related]
2. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway.
Kato Y; Tabata K; Kimura T; Yachie-Kinoshita A; Ozawa Y; Yamada K; Ito J; Tachino S; Hori Y; Matsuki M; Matsuoka Y; Ghosh S; Kitano H; Nomoto K; Matsui J; Funahashi Y
PLoS One; 2019; 14(2):e0212513. PubMed ID: 30811474
[TBL] [Abstract][Full Text] [Related]
3. Targeting TREM2 on tumor-associated macrophages enhances immunotherapy.
Binnewies M; Pollack JL; Rudolph J; Dash S; Abushawish M; Lee T; Jahchan NS; Canaday P; Lu E; Norng M; Mankikar S; Liu VM; Du X; Chen A; Mehta R; Palmer R; Juric V; Liang L; Baker KP; Reyno L; Krummel MF; Streuli M; Sriram V
Cell Rep; 2021 Oct; 37(3):109844. PubMed ID: 34686340
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma.
Lee AH; Sun L; Mochizuki AY; Reynoso JG; Orpilla J; Chow F; Kienzler JC; Everson RG; Nathanson DA; Bensinger SJ; Liau LM; Cloughesy T; Hugo W; Prins RM
Nat Commun; 2021 Nov; 12(1):6938. PubMed ID: 34836966
[TBL] [Abstract][Full Text] [Related]
5. Obesity induces PD-1 on macrophages to suppress anti-tumour immunity.
Bader JE; Wolf MM; Lupica-Tondo GL; Madden MZ; Reinfeld BI; Arner EN; Hathaway ES; Steiner KK; Needle GA; Hatem Z; Landis MD; Faneuff EE; Blackman A; Wolf EM; Cottam MA; Ye X; Bates ME; Smart K; Wang W; Pinheiro LV; Christofides A; Smith D; Boussiotis VA; Haake SM; Beckermann KE; Wellen KE; Reinhart-King CA; Serezani CH; Lee CH; Aubrey C; Chen H; Rathmell WK; Hasty AH; Rathmell JC
Nature; 2024 Jun; 630(8018):968-975. PubMed ID: 38867043
[TBL] [Abstract][Full Text] [Related]
6. Immune Escape After Adoptive T-cell Therapy for Malignant Gliomas.
Wildes TJ; Dyson KA; Francis C; Wummer B; Yang C; Yegorov O; Shin D; Grippin A; Dean BD; Abraham R; Pham C; Moore G; Kuizon C; Mitchell DA; Flores CT
Clin Cancer Res; 2020 Nov; 26(21):5689-5700. PubMed ID: 32788225
[TBL] [Abstract][Full Text] [Related]
7. Increasing Tumor Extracellular pH by an Oral Alkalinizing Agent Improves Antitumor Responses of Anti-PD-1 Antibody: Implication of Relationships between Serum Bicarbonate Concentrations, Urinary pH, and Therapeutic Outcomes.
Ando H; Emam SE; Kawaguchi Y; Shimizu T; Ishima Y; Eshima K; Ishida T
Biol Pharm Bull; 2021; 44(6):844-852. PubMed ID: 34078817
[TBL] [Abstract][Full Text] [Related]
8. Targeting myeloid checkpoint Siglec-10 reactivates antitumor immunity and improves anti-programmed cell death 1 efficacy in gastric cancer.
Lv K; Sun M; Fang H; Wang J; Lin C; Liu H; Zhang H; Li H; He H; Gu Y; Li R; Shao F; Xu J
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37935567
[TBL] [Abstract][Full Text] [Related]
9. Discovery of a Novel CSF-1R Inhibitor with Highly Improved Pharmacokinetic Profiles and Superior Efficacy in Colorectal Cancer Immunotherapy.
Lv Q; Yang H; Wang D; Zhou H; Wang J; Zhang Y; Wu D; Xie Y; Lv Y; Hu L; Wang J
J Med Chem; 2024 Apr; 67(8):6854-6879. PubMed ID: 38593344
[TBL] [Abstract][Full Text] [Related]
10. TREM2 deficiency reprograms intestinal macrophages and microbiota to enhance anti-PD-1 tumor immunotherapy.
Di Luccia B; Molgora M; Khantakova D; Jaeger N; Chang HW; Czepielewski RS; Helmink BA; Onufer EJ; Fachi JL; Bhattarai B; Trsan T; Rodrigues PF; Hou J; Bando JK; da Silva CS; Cella M; Gilfillan S; Schreiber RD; Gordon JI; Colonna M
Sci Immunol; 2024 May; 9(95):eadi5374. PubMed ID: 38758808
[TBL] [Abstract][Full Text] [Related]
11. Carfilzomib modulates tumor microenvironment to potentiate immune checkpoint therapy for cancer.
Zhou Q; Liang J; Yang T; Liu J; Li B; Li Y; Fan Z; Wang W; Chen W; Yuan S; Xu M; Xu Q; Luan Z; Xia Z; Zhou P; Huang Y; Chen L
EMBO Mol Med; 2022 Jan; 14(1):e14502. PubMed ID: 34898004
[TBL] [Abstract][Full Text] [Related]
12. Absence of central tolerance in Aire-deficient mice synergizes with immune-checkpoint inhibition to enhance antitumor responses.
Benitez AA; Khalil-Agüero S; Nandakumar A; Gupta NT; Zhang W; Atwal GS; Murphy AJ; Sleeman MA; Haxhinasto S
Commun Biol; 2020 Jul; 3(1):355. PubMed ID: 32641748
[TBL] [Abstract][Full Text] [Related]
13. Targeting metabolic sensing switch GPR84 on macrophages for cancer immunotherapy.
Li J; Ma A; Zhang R; Chen Y; Bolyard C; Zhao B; Wang C; Pich T; Li W; Sun N; Ma Q; Wen H; Clinton SK; Carson WE; Li Z; Xin G
Cancer Immunol Immunother; 2024 Feb; 73(3):52. PubMed ID: 38349405
[TBL] [Abstract][Full Text] [Related]
14. Leptin Augments Antitumor Immunity in Obesity by Repolarizing Tumor-Associated Macrophages.
Dudzinski SO; Bader JE; Beckermann KE; Young KL; Hongo R; Madden MZ; Abraham A; Reinfeld BI; Ye X; MacIver NJ; Giorgio TD; Rathmell JC
J Immunol; 2021 Dec; 207(12):3122-3130. PubMed ID: 34772698
[TBL] [Abstract][Full Text] [Related]
15. CD276-dependent efferocytosis by tumor-associated macrophages promotes immune evasion in bladder cancer.
Cheng M; Chen S; Li K; Wang G; Xiong G; Ling R; Zhang C; Zhang Z; Han H; Chen Z; Wang X; Liang Y; Tian G; Zhou R; Zhu Y; Ma J; Liu J; Lin S; Xu H; Chen D; Li Y; Peng L
Nat Commun; 2024 Apr; 15(1):2818. PubMed ID: 38561369
[TBL] [Abstract][Full Text] [Related]
16. KERS-Inspired Nanostructured Mineral Coatings Boost IFN-γ mRNA Therapeutic Index for Antitumor Immunotherapy.
Shao Z; Chen L; Zhang Z; Wu Y; Mou H; Jin X; Teng W; Wang F; Yang Y; Zhou H; Xue Y; Eloy Y; Yao M; Zhao S; Cui W; Yu X; Ye Z
Adv Mater; 2023 Dec; 35(51):e2304296. PubMed ID: 37587307
[TBL] [Abstract][Full Text] [Related]
17. Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti-PD-1 Immunotherapy.
Liu Y; Wang H; Zhao X; Zhang J; Zhao Z; Lian X; Zhang J; Kong F; Hu T; Wang T; Li X; Wang L; Wang D; Li C; Luan H; Liu X; Wang C; Jiang Y; Li X; Li F; Ji S; Wang Y; Li Z
Cancer Res; 2023 Oct; 83(20):3385-3399. PubMed ID: 37506192
[TBL] [Abstract][Full Text] [Related]
18. Bexmarilimab Activates Human Tumor-Associated Macrophages to Support Adaptive Immune Responses in Interferon-Poor Immune Microenvironments.
Rannikko JH; Bono P; Hynninen J; Hollmén M
Cancer Immunol Res; 2024 Jan; 12(1):48-59. PubMed ID: 37922365
[TBL] [Abstract][Full Text] [Related]
19. Immunometabolic actions of trabectedin and lurbinectedin on human macrophages: relevance for their anti-tumor activity.
Povo-Retana A; Fariñas M; Landauro-Vera R; Mojena M; Alvarez-Lucena C; Fernández-Moreno MA; Castrillo A; de la Rosa Medina JV; Sánchez-García S; Foguet C; Mas F; Marin S; Cascante M; Boscá L
Front Immunol; 2023; 14():1211068. PubMed ID: 37675104
[TBL] [Abstract][Full Text] [Related]
20. Trabectedin Enhances Oncolytic Virotherapy by Reducing Barriers to Virus Spread and Cytotoxic Immunity in Preclinical Pediatric Bone Sarcoma.
Ringwalt EM; Currier MA; Glaspell AM; Chen CY; Cannon MV; Cam M; Gross AC; Gust M; Wang PY; Boon L; Biederman LE; Schwarz E; Rajappa P; Lee DA; Mardis ER; Carson WE; Roberts RD; Cripe TP
bioRxiv; 2024 Mar; ():. PubMed ID: 38464161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
